Tenoxicam
Brand names: Mobiflex
Tenoxicam is a non-steroidal anti-inflammatory drug of the oxicam class used for the relief of pain and inflammation in rheumatic conditions such as osteoarthritis and rheumatoid arthritis.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It inhibits cyclo-oxygenase enzymes, reducing prostaglandin synthesis and thereby producing anti-inflammatory and analgesic effects.
Prescribing in practice
- Like other NSAIDs it increases the risk of serious gastrointestinal bleeding, ulceration and perforation, and cardiovascular and renal adverse events, so it should be used at the lowest effective dose for the shortest duration.
- Caution is needed in older people and in those with cardiovascular disease, renal impairment, asthma or a history of peptic ulceration; gastroprotection should be considered where appropriate.
- It interacts with anticoagulants, antiplatelets, other NSAIDs, diuretics, ACE inhibitors and lithium, increasing the risk of bleeding or renal toxicity.
Monitoring
Monitor renal function and blood pressure, and review for gastrointestinal symptoms, particularly in higher-risk patients and on long-term use.
Counselling the patient
- Take it with or after food and report indigestion, black stools or vomiting blood.
- Avoid taking other anti-inflammatory painkillers at the same time unless advised.
- Seek advice if you develop swelling, breathlessness or reduced urine output.
Evidence & guidelines
NICE and MHRA advise NSAIDs be used at the lowest effective dose for the shortest time owing to gastrointestinal and cardiovascular risks.
Reference: NICE; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Cutaneous Lupus Erythematosus · BAD; EULAR
- Osteoporosis / Fragility Fracture · NOGG 2021; NICE NG147; NG224
- Arteritic AION (Giant Cell Arteritis) · RCOphth; BSR
- Osteoarthritis Hip / Knee Management · NICE NG226 (2022)
- Lupus Nephritis · EULAR/ERA-EDTA 2019; KDIGO 2024
- Rheumatoid Arthritis Management · NICE CG79 2018 / EULAR 2022